Compare FMS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMS | CYTK |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | Germany | United States |
| Employees | 108165 | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 10.7B |
| IPO Year | N/A | 2004 |
| Metric | FMS | CYTK |
|---|---|---|
| Price | $24.58 | $80.74 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 19 |
| Target Price | $30.00 | ★ $89.26 |
| AVG Volume (30 Days) | 577.2K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | $3.83 | $310.19 |
| P/E Ratio | $15.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.02 | $32.89 |
| 52 Week High | $27.64 | $88.31 |
| Indicator | FMS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 53.54 |
| Support Level | $22.47 | $59.07 |
| Resistance Level | $27.40 | $88.31 |
| Average True Range (ATR) | 0.29 | 2.90 |
| MACD | 0.02 | -0.56 |
| Stochastic Oscillator | 97.64 | 45.23 |
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.